BRAF and ameloblastoma: The genetic testing of the BRAF V600E mutation in Black and mixed-race patients in the United States is worth future study, as the heterogeneity and genetic diversity of the population in the United States may shed additional insights into the role of BRAF V600E on primary and recurrent ameloblastomas, as well as lead to targeted non-surgical treatment options.